Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens.

Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens.

Item
http://www.wikidata.org/entity/Q33398587
Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study.Oliguria as an early indicator of mortality risk in patients with multiple myeloma and renal impairment.Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen.Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial.The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment.Comparison of the Freiburg and Charlson comorbidity indices in predicting overall survival in elderly patients with newly diagnosed multiple myeloma.Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma.Prognostic Significance of Initial Serum Albumin and 24 Hour Daily Protein Excretion before Treatment in Multiple Myeloma.Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study.Current treatments for renal failure due to multiple myeloma.Restoration of renal function in patients with newly diagnosed multiple myeloma is not associated with improved survival: a population-based study.Lenalidomide is effective and safe for the treatment of patients with relapsed multiple myeloma and very severe renal impairment.Renal impairment in patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes syndrome: incidence, treatment and outcome.Prognostic value of the inverse platelet to lymphocyte ratio (iPLR) in patients with multiple myeloma who were treated up front with a novel agent-containing regimen.Bortezomib overcomes the negative prognostic impact of renal impairment in a newly diagnosed elderly patient with multiple myeloma: A case report.
P2860

Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens.

Item
http://www.wikidata.org/entity/Q33398587
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Renal impairment is not an ind ...... th novel agent-based regimens.
@ast
Renal impairment is not an ind ...... th novel agent-based regimens.
@en
type
label
Renal impairment is not an ind ...... th novel agent-based regimens.
@ast
Renal impairment is not an ind ...... th novel agent-based regimens.
@en
prefLabel
Renal impairment is not an ind ...... th novel agent-based regimens.
@ast
Renal impairment is not an ind ...... th novel agent-based regimens.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P356
P1433
P1476
Renal impairment is not an ind ...... th novel agent-based regimens.
@en
P2093
P2860
P304
P31
P356
10.3109/10428194.2011.597906
P433
P478
P50
P577
P698